(HealthDay)—Lutetium-177 (177Lu)-prostate-specific membrane antigen (PSMA)-617 radioligand therapy added to standard care is beneficial for patients with advanced PSMA-positive metastatic castration-resistant prostate cancer, ...
Jul 6, 2021
0
0
(HealthDay)—For patients with refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), three- and five-year overall survival (OS) and progression-free survival (PFS) are similar with allogeneic or autologous hematopoietic ...
Jun 10, 2021
0
1
Adding sintilimab to a regimen of gemcitabine and platinum demonstrates clinical benefit over gemcitabine and platinum alone as first-line therapy in patients with locally advanced or metastatic squamous cell non-small cell ...
May 25, 2021
0
1
Precision oncology has led to approved, molecularly specific, biomarker-defined indications for targeted therapies. With the number of validated drug targets increasing, testing each patient's tumor for all markers related ...
Apr 30, 2021
0
0
Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy—an abnormal number of chromosomes—tend to respond better to immune checkpoint inhibitor drugs than patients with higher ...
Apr 11, 2021
0
17
Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led by researchers at the UCLA Jonsson Comprehensive Cancer Center found using a bilateral attack instead of the conventional ...
Apr 11, 2021
0
4
(HealthDay)—For patients with advanced squamous non-small cell lung cancer (sq- NSCLC), adding tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS), according to a study ...
Apr 5, 2021
0
2
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
Feb 25, 2021
0
24
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from ...
Feb 13, 2021
0
5
(HealthDay)—The Burkitt lymphoma (BL) International Prognostic Index (BL-IPI) provides robust discrimination of survival and can be used for prognostication, according to a study published online Jan. 27 in the Journal ...
Feb 12, 2021
0
2
